Literature DB >> 12813164

First proteasome inhibitor approved for multiple myeloma.

Renee Twombly.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813164     DOI: 10.1093/jnci/95.12.845

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  14 in total

Review 1.  Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures.

Authors:  Maurizio Bendandi
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

Review 2.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

Review 3.  Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Authors:  Ania C Muntau; João Leandro; Michael Staudigl; Felix Mayer; Søren W Gersting
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

Review 4.  The integrated stress response and proteotoxicity in cancer therapy.

Authors:  David J McConkey
Journal:  Biochem Biophys Res Commun       Date:  2017-02-03       Impact factor: 3.575

5.  Proteasome Inhibition After Burn Injury.

Authors:  P Geoff Vana; Heather M LaPorte; Yee M Wong; Richard H Kennedy; Richard L Gamelli; Matthias Majetschak
Journal:  J Burn Care Res       Date:  2016 Jul-Aug       Impact factor: 1.845

6.  TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.

Authors:  Prahlad V Raninga; Giovanna Di Trapani; Slavica Vuckovic; Kathryn F Tonissen
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

7.  Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats.

Authors:  Harold H Bach; Heather M Laporte; Yee M Wong; Richard L Gamelli; Matthias Majetschak
Journal:  J Trauma Acute Care Surg       Date:  2013-02       Impact factor: 3.313

8.  Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Authors:  Megan Y Murray; Lyubov Zaitseva; Martin J Auger; Jenny Io Craig; David J MacEwan; Stuart A Rushworth; Kristian M Bowles
Journal:  Cell Cycle       Date:  2015-01-07       Impact factor: 4.534

9.  Different Stability and Proteasome-Mediated Degradation Rate of SMN Protein Isoforms.

Authors:  Denise Locatelli; Mineko Terao; Mami Kurosaki; Maria Clara Zanellati; Daniela Rita Pletto; Adele Finardi; Francesca Colciaghi; Enrico Garattini; Giorgio Stefano Battaglia
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

10.  Trichothecin induces cell death in NF-κB constitutively activated human cancer cells via inhibition of IKKβ phosphorylation.

Authors:  Jia Su; Peiji Zhao; Lingmei Kong; Xingyao Li; Juming Yan; Ying Zeng; Yan Li
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.